drugset / Trial / NCT02197026

Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis

NCT02197026

Phase 4 Completed 518 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of treatment cost of knee osteoarthritis (OA) in patients treated with Synvisc® versus usual treatments as well as evaluation of safety and effectiveness of these treatments.

Timeline

Start
1998-10
Primary completion
2000-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hylan G-F 20 Other / unclassified Other

Indications